MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'denosumab'. Sat, 03 Sep 2011 02:32:02 +0100 http://www.medworm.com/index.php?rid=3767316&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FxlFc75cttOY%2F Hello, everyone, and welcome back. We hope your weekend was relaxing, despite the heat. Now, of course, the time has come to return to the routine as meetings and deadlines beckon. So please join us for the mandatory cup of stimulation as we scan the news of the world. Hope your day goes well and do stay in touch… AIDS Drug Cocktails Halve New Cases (Reuters) A J&J/Merck Plant Gets Flagged By The FDA (CNN Money) Sigma Pharma Receives Multiple Bids (Reuters) Teva And Sun Losing Patent Ruling On Protonix (PharmaTimes) Genetic Testing, Mix-Ups And Federal Oversight (The Washington Post) Vaginal Sex Gel Test Results To Be Released (Bloomberg News) Charles River Shareholders Says Wuxi Deal Is Inadequate (OutsourcingPharma) Amgen Gets Priority Review For Prolia (Associated Press) (Sou... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3767316 Mon, 19 Jul 2010 11:38:26 +0100 3767316 http://www.medworm.com/index.php?rid=3490830&cid=t_176570_136_f&fid=37846&url=http%3A%2F%2Fhealthinfoispower.wordpress.com%2F2010%2F04%2F20%2Fexpression-of-proteins-linked-to-poor-outcome-in-women-with-ovarian-cancer%2F Scientists have established the presence of certain proteins in ovarian cancer tissues and have linked these proteins to poor survival rates in women with advanced stages of the disease. Scientists have established the presence of certain proteins in ovarian cancer tissues and have linked these proteins to poor survival rates in women with advanced [...] (Source: Libby's H*O*P*E*) Libby's H*O*P*E* blogs http://www.medworm.com/rss/comments.php?id=3490830 Wed, 21 Apr 2010 00:09:14 +0100 3490830 http://www.medworm.com/index.php?rid=3254723&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FCKQE3vGwPJU%2F Hello, everyone. Nice to see you again. Another busy day awaits, yes? Many of you are dashing about the BIO gathering in New York. Meanwhile, there are forecasts of still more snow in some parts of our readership area. Business cards in one hand. A shovel in the other. Meanwhile, we are about to wake the short people for another day at the schoolhouse. So while we brace for our various activities, here are a few items to see you through. All best… Amgen’s D-mab Helps Fractures In Prostate Cancer Patient (Bloomberg) Lilly’s CEO Got $20.9M In ‘09 Compensation (Indianapolis Star) FDA Clears Wider Use Of Crestor (Reuters) Most Glaxo Job Cuts To Come From The UK (The Harlow Herald) Pfizer Gives Trovan Documents To Nigerian Authorities (ThisDay) Merck Sorono’s Lawye... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3254723 Tue, 09 Feb 2010 12:33:43 +0100 3254723 http://www.medworm.com/index.php?rid=2719939&cid=t_176570_136_f&fid=35294&url=http%3A%2F%2Fwww.psa-rising.com%2Fblog%2F2009%2F08%2Fdenosumab-in-men-receiving-androgen-deprivation-therapy-for-prostate-cancer%2F Androgen-deprivation therapy is well-established for treating prostate cancer but is associated with bone loss and an increased risk of fracture. Matthew R. Smith and an international team investigated the effects of denosumab, a fully human monoclonal antibody against receptor activator of nuclear factor-{kappa}B ligand, on bone mineral density and fractures in men receiving androgen-deprivation therapy [...] (Source: psa-rising.com/blog) psa-rising.com/blog blogs http://www.medworm.com/rss/comments.php?id=2719939 Thu, 20 Aug 2009 12:48:46 +0100 2719939 http://www.medworm.com/index.php?rid=1945450&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F445453882%2F The past 18 months were not terribly kind to Kevin Sharer. There were FDA warnings over health risks associated with the Aranesp and Epogen anemia meds and reduced Medicare reimbursement. Congress is investigating marketing practices. The SEC is probing a failure to disclose that a key clinical trial ended over safety concerns. There were layoffs. And he was named one of the worst CEOs. But Kevin is unflaggingly optimistic and predicts the fallout from safety concerns and reimbursement cuts for its anemia meds should bottom out during the first half of 2009. And he tells The Wall Street Journal this should bolster Amgen’s standing as it prepares for the anticipated approval and launch of denosumab, a new drug for osteoporosis, which may receive FDA approval next year. Kevin acknowled... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1945450 Fri, 07 Nov 2008 13:05:43 +0100 1945450 http://www.medworm.com/index.php?rid=1802935&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F394258319%2F After months of hype, the results from a long-awaited trial show that denosumab reduced the risk of verterbral fractures in post-menopausal women by 68 percent compared with those given a placebo. This places Amgen’s med on a par with Novartis’ Reclast drug, which is the most effective on the market. Although some investors hoped denosumab’s effectiveness would exceed 70 percent, the results suggest Amgen has a very competitive product in a big market. The stock is up more than 5 percent in the first hour of trading after the findings were made public. The three-year study involved 7,808 women and found that 60 mg of denosumab given every six months reduced the risk of new vertebral fractures by 68 percent versus placebo - 2.3 percent on denosumab versus 7.2 percent on pl... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1802935 Tue, 16 Sep 2008 14:45:45 +0100 1802935 http://www.medworm.com/index.php?rid=1798523&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F393518130%2F The important data is released tomorrow, but the biotech has other study results to share about denosumab - subcutaneous injections every six months achieved significantly greater increases in bone mineral density compared with Merck’s Fosamax at all sites measured. For the primary endpoint, denosumab resulted in significant increases in BMD at the total hip - 1.9 percent versus 1.05 percent (here is the statement). This may encourage Amgen employees and investors, but the big issue is whether denosumab significantly reduced the risk of spine fracture in a three-year trial of 7,800 post-menopausal women. Amgen released partial results this summer, but never disclosed how much the risk was reduced. That’s what everyone is waiting to hear on Tuesday at the annual meeting of the Ameri... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1798523 Mon, 15 Sep 2008 22:39:48 +0100 1798523 http://www.medworm.com/index.php?rid=1790484&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F390987933%2F Next Tuesday, the struggling biotech releases data about denosumab, an experimental osteoporosis drug, and the data could make the difference between a multi-billion-dollar med and an also-ran in a crowded field. No small moment for a company that has staggered from setback to setback with its existing meds. “Denosumab is a mega-blockbuster opportunity and will now emerge as the principal long-term value driver,” Morgan Stanley analyst Steven Harr wrote in a recent research note, Reuters reports. “We see a high probability of regulatory success given data to date.” Two months ago, Amgen reported denosumab significantly reduced the risk of spine fracture in a three-year trial of 7,800 post-menopausal women, but never disclosed exactly how much the risk was reduced. T... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1790484 Fri, 12 Sep 2008 21:02:46 +0100 1790484 http://www.medworm.com/index.php?rid=1786187&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F388586261%2F A shiny day here in the nation’s medicine chest. And as always, there is much to do preparing for our own meetings and deadlines. This can mean only one thing - time to grab our ritual cup of stimulation. So as you reach for your own, here are a few items to help your day get started. All best… Amgen In No Rush For Bone Drug Partner (Dow Jones) Takeda Is Coy About Its Future With Alizyme (Bloomberg News) Novartis Meningitis Drug May Protect Older Infants (Yahoo/Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1786187 Wed, 10 Sep 2008 11:29:52 +0100 1786187 http://www.medworm.com/index.php?rid=1660995&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F348345167%2F Late Friday, the biotech released partial study results showing its experimental osteoporosis drug, denosumab, significantly reduced the risk of bone fracture in post-menopausal women in a large number of patients, triggering a rise of nearly 18 percent in its shares in after-hours trading. That’s because denosumab, which targets a protein involved with bone-destroying cells, is seen as a key to Amgen’s future since the growth of its flagship anemia drugs - Epogen and Aranesp - have faltered over safety concerns that have brought Black Box warnings. Even before the after-hours run-up to $63.49, Amgen shares have climbed about 28 percent over the last three months. In a research note this morning, Rodman & Renshaw analyst Michael King writes that “the worst is behind ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1660995 Mon, 28 Jul 2008 12:31:44 +0100 1660995 http://www.medworm.com/index.php?rid=1623065&cid=t_176570_136_f&fid=36051&url=http%3A%2F%2Ffeeds.b5media.com%2F%7Er%2Fb5media%2FCancerCommentary%2F%7E3%2F335918405%2F In this study of more than 1,400 men, denosumab treatment produced statistically significantly greater increases in bone mineral density (BMD) at the lumbar spine (primary endpoint) and non-vertebral sites compared with placebo at multiple time points. These improvements in BMD were consistent with those seen in other denosumab studies evaluating BMD in women with breast cancer receiving aromatase inhibitor therapy, and in post-menopausal women with low bone mass. During the 36-month evaluation period, men receiving denosumab experienced less than half the incidence of new vertebral fractures (a secondary endpoint) compared with those receiving placebo, a statistically significant finding. Furthermore, in the denosumab arm there were fewer non-vertebral fractures over the 36-month period. ... Cancer Commentary blogs http://www.medworm.com/rss/comments.php?id=1623065 Tue, 15 Jul 2008 09:26:13 +0100 1623065 http://www.medworm.com/index.php?rid=1622995&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F335611506%2F A busy day here on the Pharmalot corporate campus where repairs were being made to the cafeteria. Nonetheless, we managed to get some work done. We hope you did as well. Meanwhile, here a few items that cropped up more recently. Have a good night and see you tomorrow… Judge Allows Abbott Class Action To Proceed (Yahoo/Reuters) Genentech Ends Studies On Drug-Combo Safety Issue (Associated Press) Amgen Drug Prevents Bone Loss In Prostate Cancer (Yahoo/Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1622995 Tue, 15 Jul 2008 01:27:24 +0100 1622995 http://www.medworm.com/index.php?rid=1622217&cid=t_176570_97_f&fid=35050&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmaGazette%2F%7E3%2F335215370%2Fdenosumab_prevents_osteoporosis_in_trial.html Amgen Inc. (NASDAQ:AMGN) announced that its experimental drug denosumab demonstrated that it can prevent bone loss in men that are being treated with prostate cancer drugs which can cause osteoporosis.Results, based on a three-year Phase III study of over 1,400 men, found that denosumab increased bone mineral density at the lumbar spine and non-vertebral sites than a placebo. All men in the study had non-metastatic prostate cancer and were undergoing androgen deprivation therapy.Amgen also stated that during the 36 months of the trial the men who received denosumab had have the incidence of new vertebral fractures than those receiving a placebo."This pivotal study in men with prostate cancer demonstrated once again that denosumab increases BMD consistently at all sites measured. ... PharmaGazette blogs http://www.medworm.com/rss/comments.php?id=1622217 Mon, 14 Jul 2008 16:00:36 +0100 1622217 http://www.medworm.com/index.php?rid=1454779&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F293841932%2F Another busy day comes to an end. We hope yours was productive and even meaningful. Now, though, the time has come to gather assorted children and loose ends, so we can take stock and prepare for another day. Hope your evening is pleasant and see you in the morning… Amgen’s Denosumab Protects Bone Density: Study (Yahoo/Reuters) Novartis Stock Jumps On Promise Of Kidney Cancer Med (Yahoo/AP) Shingle Victims’ Relatives Should Get Zostavax: Study (Bloomberg News) What Pharma Is Donating To Asian Disasters (Yahoo/AP) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1454779 Mon, 19 May 2008 23:30:46 +0100 1454779 http://www.medworm.com/index.php?rid=1446424&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F291382043%2F Some folks will be pulling all-nighters reading the abstracts released by the American Society of Clinical Oncology this evening. (Please look here). But if you simply want to glean a few highlights, here are the latest news summaries moving over our transom… Lilly Drug Slows Lung Cancer (The Wall Street Journal) Rash Most Common Side Effect In Vectibix Trials (Yahoo/Reuters) Avastin Improves Brain Cancer Survival (Yahoo/Reuters) Herceptin Enhances Tykerb For Breast Cancer (Yahoo/Reuters) Amgen Says Denosumab Combats Rare Bone Tumors (Yahoo/Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1446424 Fri, 16 May 2008 03:42:00 +0100 1446424 http://www.medworm.com/index.php?rid=1347611&cid=t_176570_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F263545183%2F Let’s take one problem at a time. First, there are fresh concerns over potentially troubling safety data from a late-stage study of the biotech’s drug for postmenopausal osteoporosis, known as denosumab. Wall Street is worried because results show the med increased bone density in both early and late stage postmenopausal women, but patients had a higher rate of infections requiring hospitalization. Amgen says its investigators don’t believe the higher infection rate is related to the drug, noting that additional studies involving patients undergoing cancer therapy, who are typically more susceptible to infection, didn’t yield higher infection rates. Just the same, Amgen shares fell. “We caution…that if not a regulatory risk, such data included in an even... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1347611 Thu, 03 Apr 2008 20:23:09 +0100 1347611